$18.96 Million in Sales Expected for Esperion Therapeutics, Inc. (NASDAQ:ESPR) This Quarter


Share on StockTwits

Analysts expect Esperion Therapeutics, Inc. (NASDAQ:ESPR) to announce $18.96 million in sales for the current fiscal quarter, Zacks Investment Research reports. Four analysts have issued estimates for Esperion Therapeutics’ earnings, with the highest sales estimate coming in at $50.00 million and the lowest estimate coming in at $8.00 million. Esperion Therapeutics reported sales of $980,000.00 during the same quarter last year, which would suggest a positive year-over-year growth rate of 1,834.7%. The firm is expected to report its next quarterly earnings report after the market closes on Tuesday, February 23rd.

According to Zacks, analysts expect that Esperion Therapeutics will report full-year sales of $236.89 million for the current financial year, with estimates ranging from $225.91 million to $268.00 million. For the next financial year, analysts expect that the firm will report sales of $80.79 million, with estimates ranging from $50.00 million to $119.60 million. Zacks’ sales averages are a mean average based on a survey of research analysts that cover Esperion Therapeutics.

Several analysts have issued reports on the company. Bank of America lowered Esperion Therapeutics from a “buy” rating to a “neutral” rating and cut their price target for the company from $52.00 to $35.00 in a report on Friday, January 15th. The Goldman Sachs Group lowered Esperion Therapeutics from a “neutral” rating to a “sell” rating and dropped their price objective for the stock from $44.00 to $24.00 in a research note on Tuesday, February 9th. Jefferies Financial Group lowered Esperion Therapeutics from a “buy” rating to a “hold” rating and dropped their price objective for the stock from $40.00 to $30.00 in a research note on Friday, February 12th. Finally, Credit Suisse Group raised Esperion Therapeutics from a “neutral” rating to an “outperform” rating and set a $45.00 price objective for the company in a research note on Tuesday, November 10th. Two research analysts have rated the stock with a sell rating, three have assigned a hold rating and seven have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $68.17.

Several large investors have recently bought and sold shares of ESPR. Marshall Wace LLP purchased a new stake in shares of Esperion Therapeutics in the first quarter worth about $186,000. Pacer Advisors Inc. purchased a new stake in shares of Esperion Therapeutics in the third quarter worth about $90,000. Patriot Financial Group Insurance Agency LLC raised its position in Esperion Therapeutics by 230.0% during the third quarter. Patriot Financial Group Insurance Agency LLC now owns 1,650 shares of the biopharmaceutical company’s stock valued at $61,000 after purchasing an additional 1,150 shares during the period. Cambridge Investment Research Advisors Inc. raised its position in Esperion Therapeutics by 122.8% during the third quarter. Cambridge Investment Research Advisors Inc. now owns 9,770 shares of the biopharmaceutical company’s stock valued at $363,000 after purchasing an additional 5,385 shares during the period. Finally, DekaBank Deutsche Girozentrale purchased a new stake in Esperion Therapeutics during the third quarter valued at approximately $370,000.

NASDAQ:ESPR traded down $0.67 during mid-day trading on Thursday, hitting $27.93. 22,094 shares of the company traded hands, compared to its average volume of 1,009,383. The stock’s fifty day moving average price is $30.00 and its 200-day moving average price is $31.54. Esperion Therapeutics has a one year low of $23.90 and a one year high of $67.59. The firm has a market cap of $778.60 million, a price-to-earnings ratio of -7.43 and a beta of 1.48.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low-density lipoprotein cholesterol in the United States. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia.

Read More: Pattern Day Trader

Get a free copy of the Zacks research report on Esperion Therapeutics (ESPR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Esperion Therapeutics (NASDAQ:ESPR)

Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.